HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NCT04619004)
HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
🩺 Plain-English Summary (8th-Grade Level)
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (123 Sites)
Showing the first 25 of 123 sites.
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- City of Hope — Duarte, California
- Moores Cancer Center at the UC San Diego Health — La Jolla, California
- Pacific Shores Medical Group — Long Beach, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- University of California at Irvine — Orange, California
- Cedars Sinai — West Hollywood, California
- University of Colorado Denver - Anschutz Medical Campus — Aurora, Colorado
- Florida Cancer Specialists - South — Fort Myers, Florida
- AdventHealth Orlando — Orlando, Florida
- Memorial Healthcare System — Pembroke Pines, Florida
- Florida Cancer Specialist-North — St. Petersburg, Florida
- Florida Cancer Specialists-Panhandle — Tallahassee, Florida
- H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida
- Florida Cancer Specialists-East — West Palm Beach, Florida
- Emory University — Dunwoody, Georgia
- Northwestern University — Chicago, Illinois
- University of Maryland - Marlene and Stewart Greenebaum Cancer Center — Baltimore, Maryland
- Massachusetts General Hospital (MGH) - Hematology/Oncology — Boston, Massachusetts
- Beth Israel Deaconess Medical Center, Harvard Medical School — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Henry Ford Cancer Institute/Henry Ford Hospital — Detroit, Michigan
- Mount Sinai Hospital — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Montefiore Medical Center — The Bronx, New York
📞 Contact the Study Coordinator
Phone: (877) 632-6789
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Small Cell Lung Cancer Metastatic
- Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer — Iowa City, Iowa
- Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination — Orange, California
Explore by condition: All Non-Small Cell Lung Cancer Metastatic clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.